ACAD
ACADIA Pharmaceuticals Inc.
Biotechnology · Healthcare · United States
20.76
close · 2026-10-29
value
77
cheaper than peers77
quality
89
stronger fundamentals89
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
caveat margins at their own peak
Value inputs
| measure | company | vs peers |
| cash flow yield, 2 years ago | 0.3% | 86 |
| earnings yield, latest year | 8.1% | 86 |
| earnings yield, 1 year ago | 4.8% | 86 |
| earnings yield, 2 years ago | -1.3% | 86 |
| cash flow yield, latest year | 2.2% | 86 |
| price to sales | 4.50× | 77 |
| cash flow yield, 1 year ago | 3.2% | 77 |
| price to book | 2.73× | 60 |
| cash flow yield, 3 years ago | -2.3% | 59 |
| earnings yield, 3 years ago | -4.7% | 50 |
| forward P/E | 22.55× | 45 |
| EV to EBITDA | 38.67× | 26 |
12 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 37.3% | 92 |
| debt to equity | 4.1% | 78 |
| operating margin | -1.7% | 77 |
| revenue growth | 9.7% | 40 |
4 of 4 measures available
Facts
| market cap | $4B |
| free cash flow | $154.1M |
| employees | 796 |
| first trade | 2004-05-27 |
| next earnings | 2026-11-04 |
| fundamentals updated | 2026-08-05 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 2.30 | 1.36 | -0.37 | -1.34 |
| free cash flow | $105.1M | $157.2M | $16.7M | -$114.0M |
| net income | $391.0M | $226.5M | -$61.3M | -$216.0M |
| revenue | $1.07B | $957.8M | $726.4M | $517.2M |
| unusual items | $0 | $146.5M | $0 | $0 |